Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 9, 2016, Pages 915-925

  Martin, F C ^a   Chenevix Trench, G ^b   Yeomans, N D ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG USE; EFFECT SIZE; HUMAN; INFORMATION RETRIEVAL; MEDICAL LITERATURE; MEDICAL RECORD REVIEW; META ANALYSIS; ODDS RATIO; PEER REVIEW; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STATISTICAL ANALYSIS; STOMACH FUNDUS GLAND; STOMACH FUNDUS GLAND POLYP; STOMACH POLYP; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84991106511     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13800     Document Type: Review

References (59)

1. Zelter A, Fernández J, Bilder C, et al. Fundic gland polyps and association with proton pump inhibitor intake: a prospective study in 1,780 endoscopies. Dig Dis Sci 2011; 56: 1743–8.
2. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, de Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24: 1341–8.
3. Ally MR, Veerappan GR, Maydonovitch CL, et al. Chronic proton pump inhibitor therapy associated with increased development of fundic gland polyps. Dig Dis Sci 2009; 54: 2617–22.
4. Carmack SW, Genta RM, Schuler CM, Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009; 104: 1524–32.
5. Mahachai V, Graham D, Odze R. Gastric polyps. In: Feldman M, ed. Uptodate. UpToDate. Waltham, MA: Wolters Kluwer, 2015. Available at: www.uptodate.com (accessed September 9, 2015).
6. Burt R. Gastric fundic gland polyps. Gastroenterology 2003; 125: 1462–9.
7. Li J, Woods Susan L, Healey S, et al. Point mutations in exon 1B of APC reveal gastric adenocarcinoma and proximal polyposis of the stomach as a familial adenomatous polyposis variant Am J Hum Genet 2016; 98: 830–42.
8. Bertoni G, Sassatelli R, Nigrisoli E, et al. Dysplastic changes in gastric fundic gland polyps of patients with familial adenomatous polyposis. Ital J Gastroenterol Hepatol 1999; 31: 192–7.
9. Worthley DL, Phillips KD, Wayte N, et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 2012; 61: 774–9.
10. Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 2009; 137: 1976–85.e1-10.
11. Graham JR. Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust 1992; 157: 287–8.
12. Dent J. Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust 1992; 157: 645.
13. Mogadam M, Houk R. Long-term use of omeprazole is associated with development of benign epithelial gastric polyps [abstract]. Am J Gastroenterol 1996; 91: 1921. Abstract 151.
14. El-Zimaity HMT, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997; 92: 1858–60.
15. Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998; 110: 615–21.
16. Collins S, Tydd T. Gastric polyps and long-term omeprazole [abstract]. J Gastroenterol Hepatol 1998; 13(suppl 12): A149.
17. Vieth M, Stolte M. Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol 2001; 116: 716–20.
18. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–12.
19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
20. Kroupa R, Jecmenova M, Dastych M, Dolina J, Hep A. Is there a real risk of the long term medical treatment of gastroesophageal reflux disease? United European Gastroenterol J 2014; 2: A264.
21. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2014. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
22. Bax L. Professional software for meta-analysis in Excel. Version 2.0.1.4. BiostatXL, 2011. Available at: http://www.meta-analysis-made-easy.com.
23. Rucker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta-analyses with binary outcomes. Stat Med 2008; 27: 746–63.
24. Jin ZC, Wu C, Zhou XH, He J. A modified regression method to test publication bias in meta-analyses with binary outcomes. BMC Med Res Methodol 2014; 14: 132.
25. Hsu WH, Wu IC, Kuo CH, et al. Influence of proton pump inhibitor use in gastrointestinal polyps. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 2010; 26: 76–83.
26. Yoshida N, Yamada S, Fukumoto K, et al. W1083 the development of fundic gland polyps associated with chronic proton pump inhibitor therapy involves in increased expression of Aquaporin 4. Gastroenterology 2010; 138: S-648.
27. Camilo SM, Almeida EC, Miranzi BA, Silva JC, Nomelini RS, Etchebehere RM. Endoscopic and histopathologic gastric changes in chronic users of proton-pump inhibitors. Arq Gastroenterol 2015; 52, 59–64.
28. Cao HL, Qu R, Zhang ZH, et al. Sporadic fundic gland polyps are not associated with proton pump inhibitors therapy but negatively correlate with Helicobacter pylori infection in China. Chin Med J (Engl) 2014; 127: 1239–43.
29. Huang CZ, Lai RX, Mai L, et al. Relative risk factors associated with the development of fundic gland polyps. Eur J Gastroenterol Hepatol 2014; 26: 1217–21.
30. Fiocca R, Mastracci L, Attwood SE, et al. Lotus Trial Collaborators. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012; 36: 959–71.
31. Declich P, Tavani E, Ferrara A, Caruso S, Bellone S. Sporadic fundic gland polyps: clinico-pathologic features and associated diseases. Pol J Pathol 2005; 56: 131–7.
32. Dickey W, Kenny BD, McConnell JB. Prevalence of fundic gland polyps in a western European population. J Clin Gastroenterol 1996; 23: 73–5.
33. Garcia-Alonso FJ, Martin-Mateos RM, Gonzalez Martin JA, Foruny JR, Vazquez-Sequeiros E, de Boixeda Miquel D. Gastric polyps: analysis of endoscopic and histological features in our center. Rev Esp Enferm Dig 2011; 103: 416–20.
34. Hongo M, Fujimoto K. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol 2010; 45: 618–24.
35. Levy MDB, Bhattacharya B. Sporadic fundic gland polyps with low-grade dysplasia: a large case series evaluating pathologic and immunohistochemical findings and clinical behavior. Am J Clin Pathol 2015; 144: 592–600.
36. Pashankar DSI, Israel DM. Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr 2002; 35: 658–62.
37. Samarasam I, Roberts-Thomson J, Brockwell D. Gastric fundic gland polyps: a clinico-pathological study from North West Tasmania. ANZ J Surg 2009; 79: 467–70.
38. Torbenson M, Lee JH, Cruz-Correa M, et al. Sporadic fundic gland polyposis: a clinical, histological, and molecular analysis. Mod Pathol 2002; 15: 718–23.
39. Graham JR. Omeprazole and gastric polyposis in humans. Gastroenterology 1993; 104: 1584.
40. Reekmans A, Naegels S, Reynaert H, Urbain D. Fundic gland polyps and chronic PPI treatment: a prospective study [abstract]. Gastroenterology 2001; 120: A244.
41. Tran-Duy A, Spaetgens B, Hoes AW, deWit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; doi: 10.1016/j.cgh.2016.05.018. [Epub ahead of print].
42. Peura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN. Safety profile of dexlansoprazole MR: a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther 2009; 30: 1010–21.
43. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006; 295: 676–80.
44. Cats A, Schenk BE, Bloemena E, et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol 2000; 31: 684–90.
45. Synnerstad I, Holm L. Omeprazole induces high intraglandular pressure in the rat gastric mucosa. Gastroenterology 1997; 112: 1221–30.
46. Watanabe N, Seno H, Nakajima T, et al. Regression of fundic gland polyps following acquisition of Helicobacter pylori. Gut 2002; 51: 742–5.
47. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17: 1481–91.
48. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295–300.
49. Chen CLA. Regression of massive polypoid stalagmites: gastric fundic gland polyposis. Am J Gastroenterol 2015; 110: S510–1.
50. Brockmeyer JR, Connolly EE, Wittchow RJ, Kothari SN. Resolution of fundic gland polyposis following laparoscopic magnetic sphincter augmentation and subsequent cessation of proton pump inhibitors. Case Rep Gastrointest Med 2015; 2015: 576263.
51. Kazantsev GB, Schwesinger WH, Heim-Hall J. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report. Gastrointest Endosc 2002; 55: 600–2.
52. Kim J-S, Chae H, Kim H-K, et al. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with omeprazole. Korean J Gastroenterol 2008; 51: 305–8.
53. Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporosis Int 2016; 27: 339–47.
54. Ye X, Liu H, Wu C, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2011; 23: 794–800.
55. Bavishi C, DuPont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34: 1269–81.
56. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008; 27: 1110–21.
57. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010; 31: 1165–77.
58. Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 2010; 24: 193–201.
59. Jalving M, Koornstra JJ, Gotz JM, et al. High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol 2003; 15: 1229–33.